ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Conversely, by specifically targeting the myristoyl pocket of BCR‐ABL1, asciminib has the potential for a more favorable safety profile than ATP‐competitive inhibitors, whilst demonstrating robust efficacy for the treatment of patients with CML‐CP who are resistant or intolerant to currently approved TKIs.